LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
STANDARD BIOTOOLS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.64+0.01 (+2.27%)
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
49.9%
Operating margin
-129.2%−92.3 pts over 5 years
Net margin
-87.8%−49.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -6.2% | -4.5% | -9.2% | -2.9% | |
| Gross profit | -5.2% | +4.7% | – | -5.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -90.4% | -36.2% | -16.7% | |
| Return on assets | -22.5% | -18.0% | -12.7% | |
| Current ratio | 3.28 | 2.17 | 4.19 | |
| Interest coverage | -12.6× | -14.3× | – | |
| Inventory turnover | 2.4× | – | 2.1× | |
| Capex to revenue | 4.8% | 9.2% | 9.7% | |
| Diluted shares | 29M | 72M | 382M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Standard Biotools generated $394.52M from operations and spent $83.05M on capital expenditure, dividends and share buybacks. 44% of that went back into the business.
Generated
$394.52M
Used
$83.05M
Capital expenditure$36.58M44%Dividends$00%Share buybacks$46.47M56%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-87.8%
×Asset turnover0.14×
×Equity multiplier1.32×
=Return on equity, FY2025-16.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -87.8% | 0.14× | 1.32× | -16.7% |
| FY2024 | -152.6% | 0.19× | 2.89× | -85.8% |
| FY2023 | -70.2% | 0.30× | -3.11× | 65.1% |
| FY2022 | -194.1% | 0.29× | 50.69× | -2895.8% |
| FY2021 | -45.4% | 0.44× | 2.57× | -50.7% |
| FY2020 | -38.4% | 0.47× | 2.01× | -36.2% |
| FY2019 | -55.3% | 0.41× | 2.52× | -57.4% |
| FY2018 | -52.2% | 0.38× | 5.74× | -114.5% |
| FY2017 | -59.4% | 0.34× | 7.05× | -143.8% |
| FY2016 | -72.8% | 0.31× | 4.02× | -90.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$74.90M
- Cash generatingOperating cash flow above zero-$74.34M
- Return on assets improvedROA up on the prior year-43.0% → -12.2%
- Earnings backed by cashOperating cash flow above net income-$74.34M vs -$74.90M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.70 → 4.19
- No dilutionShare count did not rise353M → 382M
- Gross margin improvedGross margin up on the prior year49.32% → 49.86%
- More efficientAsset turnover rose0.28 → 0.14